HMNC Brain Health

HMNC Brain Health

Private
Munich, BavariaHealthcare & Life Scienceshttps://www.hmnc-brainhealth.com

Last Round

Series B

Oct 20, 2022

Total Funding Raised

$24.6M

Company Overview

HMNC Brain Health is a clinical-stage biopharmaceutical company that pioneers precision psychiatry by developing personalized therapies for mental health disorders. The company focuses on Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). It utilizes advanced AI, deep genomic insights, and predictive companion diagnostics to create targeted treatments, aiming to increase remission rates and shorten treatment durations. The company's pipeline includes co-developing first-in-class pharmaceuticals with proprietary genetic tests to identify patient groups most likely to benefit. HMNC Brain Health has operations in Germany and the United States and is backed by venture capital firms and family offices.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Mental Health, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Hardware Sales

AI Layer

Application

Keywords

precision psychiatrycompanion diagnosticstreatment-resistant depressionTRDgenetic biomarkersmajor depressive disorderMDDketamine therapyoral esketaminepharmacogenomicsAI drug discoverydrug-diagnostic combinationsmental health therapeuticspharma partnershipsclinical-stage biopharmapsychedelic therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HMNC Brain Health Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

HMNC Brain Health Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BOct 20, 2022
Convertible DebtJul 28, 2021

HMNC Brain Health Investors

Notable investors and investment history

InvestorRounds
KundK-investSeries B
Jahr GroupSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 13, 2025

    Presented new analysis supporting a genetic patient selection tool and vasopressin V1b receptor antagonist for depression treatment.

  • Oct 13, 2025

    Presented at the ISCTM Conference in Amsterdam.

HMNC Brain Health Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HMNC Brain Health Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HMNC Brain Health's valuation, stock price, and market status.

Firmographic Details

HeadquartersMunich, Bavaria
Employee Range29
Year Founded2010
Last FundingOct 20, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.